Jazz Pharmaceuticals PLC $JAZZ Shares Sold by MassMutual Private Wealth & Trust FSB

MassMutual Private Wealth & Trust FSB cut its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 58.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,426 shares of the specialty pharmaceutical company’s stock after selling 10,629 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Jazz Pharmaceuticals were worth $979,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Farther Finance Advisors LLC boosted its holdings in Jazz Pharmaceuticals by 754.8% in the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 234 shares during the last quarter. Hantz Financial Services Inc. raised its position in shares of Jazz Pharmaceuticals by 471.4% during the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 297 shares in the last quarter. Geneos Wealth Management Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 137 shares during the period. GAMMA Investing LLC lifted its holdings in Jazz Pharmaceuticals by 30.7% in the third quarter. GAMMA Investing LLC now owns 655 shares of the specialty pharmaceutical company’s stock worth $86,000 after acquiring an additional 154 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in Jazz Pharmaceuticals in the first quarter valued at approximately $90,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Rick E. Winningham sold 5,500 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $180.86, for a total value of $994,730.00. Following the completion of the transaction, the director directly owned 8,893 shares of the company’s stock, valued at approximately $1,608,387.98. This trade represents a 38.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Heather Ann Mcsharry sold 3,415 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $177.78, for a total value of $607,118.70. Following the transaction, the director directly owned 20,449 shares in the company, valued at approximately $3,635,423.22. This trade represents a 14.31% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 123,791 shares of company stock worth $21,991,850. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $160.25 on Friday. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $182.99. The firm’s 50 day moving average is $163.37 and its 200-day moving average is $137.06. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $9.74 billion, a price-to-earnings ratio of -26.40, a PEG ratio of 0.79 and a beta of 0.27.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of recent research reports. Bank of America raised their target price on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. JPMorgan Chase & Co. decreased their price objective on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a report on Monday, October 27th. Morgan Stanley reiterated an “overweight” rating and issued a $225.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday. Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. Finally, Robert W. Baird raised their price target on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. Thirteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $201.80.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.